The primary objective of the study is to understand how common fatty liver disease, which has a new updated name called Steatotic Liver Disease (SLD) or metabolic dysfunction associated steatotic liver disease (MASLD), is seen in pregnant people and if it affects pregnancy health and outcomes. This study assesses liver health throughout pregnancy and after delivery. 
   
Fatty liver disease, or SLD, is a silent disease without symptoms and is caused by fat collection in the liver. If left undiagnosed, it can progress to cirrhosis (liver damage due to scarring), liver cancer, or liver failure. It is also closely related to other conditions such as diabetes, high cholesterol, and being overweight, and it may influence pregnancy.

This study hopes to evaluate individuals for fatty liver disease by performing a quick ultrasound of the liver during a routine anatomy scan of the baby and by performing a fibroscan, a non-invasive, ultrasound-like test that looks at the amount of fat and scarring in the liver. A test tube of 1-2 teaspoons of blood will also be collected for analysis. If participants are found to have significant fat or scarring in their liver, they can be further evaluated.
   
The study duration lasts from the initial consent at the first prenatal visit and up until 1 year postpartum. Research visits are conducted at the initial ultrasound, 24-32 weeks prenatal visit, 6 months, and 1 year postpartum.